The longer AVR keep it inhouse the more valuable it will become. The major shareholder is not in for a 100% gain. There are very likely more potential bidders and Edwards and Medtronics. A number of Wall St analysts (Brokerage houses) are very familiar with AVR, but are obviously not going a write a report on an Australain stock. It's no coincidence that the 2 major companies mentioned have seen their share prices fall in relative terms far more than the Index. Raising money is not an issue. ..when, how much are the issue...will it be in stages? The FDA are well behind in approvals and thus for our EFS approval is impacted. It will only be 15-20 people and will have a significant rebate and therefore will not be tremendously expensive. Plenty going on in Europe....I could go on.
Doesnt help with a valuation, but there are plenty of those guesses around, suffice to say its a lot more than the close today
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)